Aytu Biopharma (AYTU) Cash from Financing Activities (2010 - 2026)

Aytu Biopharma (AYTU) has 17 years of Cash from Financing Activities data on file, last reported at $872000.0 in Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 79.72% year-over-year to $872000.0 in Q1 2026; TTM through Mar 2026 was $9.9 million, a 181.35% increase from a year earlier, with the FY2025 full-year figure at $15.4 million, up 1323.69% from the prior year.
• Cash from Financing Activities for Q1 2026 stood at $872000.0, up from -$6.3 million in the prior quarter.
• Over the last five years, Cash from Financing Activities for AYTU reached as high as $13.6 million in Q3 2022 and fell as low as -$6.3 million in Q4 2025.
• Historically, Cash from Financing Activities has averaged $1.2 million across 5 years, with a median of $872000.0 in 2026.
• Across the five-year window, Cash from Financing Activities slumped 2090.48% in 2024 and soared 1116.57% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at -$1.9 million in 2022, then soared by 93.24% to -$126000.0 in 2023, then slumped by 2090.48% to -$2.8 million in 2024, then sank by 126.92% to -$6.3 million in 2025, then surged by 113.92% to $872000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Financing Activities figures were $872000.0 in Q1 2026, -$6.3 million in Q4 2025, and $2.3 million in Q3 2025.